X0609 4 2026-04-10 0001806310 Taysha Gene Therapies, Inc. TSHA 0001665124 Nagendran Sukumar false C/O TAYSHA GENE THERAPIES, INC. 3000 PEGASUS PARK DRIVE, SUITE 1430 DALLAS TX 75247 true true false false President and Head of R&D 1 Common Stock 2026-04-10 4 M 0 19021 1.71 A 1336410 D Common Stock 2026-04-10 4 S 0 200000 4.46 D 1136410 D Employee Stock Option (right to buy) 1.71 2026-04-10 4 M 0 19021 0 D 2034-01-02 Common Stock 19021 455920 D This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.335 to $4.625 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. 25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. /s/ Kamran Alam, Attorney-in-Fact 2026-04-13